3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Immunoproliferative Disorders
2
Immune System Diseases
2
Cytokine Release Syndrome
2
Breast Neoplasms
2
Triple Negative Breast Neoplasms
1
Thymoma
1
Thymic epithelial tumor
1
Stomach Neoplasms
1
Prostatic Neoplasms
1
Neurotoxicity Syndromes
1
Neoplasm, Residual
1
Neoplasm Metastasis
1
Myelodysplastic Syndromes
1
Lymphoproliferative Disorders
1
Lymphoma, Non-Hodgkin
1
Lymphoma, B-Cell
1
Lymphoma
1
Lymphohistiocytosis, Hemophagocytic
1
Lymphatic Diseases
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia
1
Hodgkin Disease
1
Epstein-Barr Virus Infections
1
Colorectal Neoplasms
1
Interventions
zanubrutinib
1
pegaspargase
1
Rituximab
1
Methylprednisolone
1
Etoposide
1
Asparaginase
1
AP 1903 reagent
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lymphohistiocytosis, Hemophagocytic
×
AP 1903 reagent
×
1 year
×
Clear all
NCT01494103
2025-07-11
DOTTI
Baylor College of Medicine
Phase 1
Active not recruiting
15 enrolled